{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:45:22Z","timestamp":1789595122834,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Ulipristal acetate (UPA) is used to treat leiomyomas, and its effect on the endometrium has been studied in biopsy material. Reversible histologic modifications were found, named progesterone receptor modulators\u2013associated endometrial changes (PAEC). However, hysterectomies from patients treated with UPA have not been analyzed. For the first time, we examined surgical specimens from 100 leiomyoma-treated patients for UPA-related endometrial changes. We analyzed the distribution of lesions, involution after treatment, and the relationship between type and extent of lesions and dosage. Clinically, 72 patients were treated with 1 cycle of UPA; 23 patients with 2 cycles, and 5 with 3 cycles. A total of 66 patients underwent surgery in the first 4\u2009wk after treatment, 24 were operated between 5 and 12\u2009wk after discontinuation of UPA, and 10 after more than 12\u2009wk after the last cycle, up to a maximum of 32\u2009wk. Histologically normal endometria were found in 41 cases and PAEC in 59 cases. PAEC consisted of irregular, cystic glands showing a flattened secretory-like epithelium with vacuolation, coexisting mitoses and apoptosis, and were found focally within cyclic endometria in 51 cases. Only in 8 cases did diffuse PAEC involve the whole endometrium, transforming it into a thick spongy cushion. PAEC also occurred in adenomyosis. There was no relationship between dosage and type and extent of lesions. Diffuse PAEC, which usually presents differential diagnoses with hyperplasia, occurred in only 8 cases, being only present during the first 4\u2009wk after discontinuation of treatment and was independent of the number of cycles administered.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000450","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T23:32:33Z","timestamp":1505345553000},"page":"575-580","source":"Crossref","is-referenced-by-count":16,"title":["Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas"],"prefix":"10.1097","volume":"37","author":[{"given":"Francisco F.","family":"Nogales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Crespo-Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Cruz-Viruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Chamorro-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230824","first-page":"285","article-title":"Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids","volume":"8","author":"Biglia","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20230824","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1933719113519178","article-title":"Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception","volume":"21","author":"Mozzanega","year":"2014","journal-title":"Reprod Sci"},{"key":"R6-20230824","first-page":"315","article-title":"Mechanism of action of ulipristal acetate for emergency contraception: a systematic review","volume":"6","author":"Rosato","year":"2015","journal-title":"Front Pharmacol"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.prp.2016.10.010","article-title":"Histomorphological changes in endometriosis in a patient treated with ulipristal: a case report","volume":"213","author":"Bateman","year":"2017","journal-title":"Pathol Res Pract"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/modpathol.2008.204","article-title":"Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator","volume":"22","author":"Ioffe","year":"2009","journal-title":"Mod Pathol"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","article-title":"Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results","volume":"208","author":"Fernandez","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-20230824","first-page":"531","article-title":"Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium","volume":"32","author":"Whitaker","year":"2017","journal-title":"Hum Reprod"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jmig.2016.01.010","article-title":"Hysteroscopic patterns in women on treatment with ulipristal acetate 5\u2009mg\/day: a preliminary study","volume":"23","author":"Bettocchi","year":"2016","journal-title":"J Minim Invasive Gynecol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004347-201811000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:33:45Z","timestamp":1692840825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004347-201811000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000450","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}